TH-Z93, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 90 nM).

ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity.

YM-53601 is a squalene synthase inhibitor (IC50s = 79 and 90 nM in HepG2 cells and rat liver microsomes, respectively).

Pseudouridimycin (PUM), an antibiotic, is a selective bacterial RNA polymerase (RNAP) inhibitor. Pseudouridimycin is a C-nucleoside analogue that is effective against both Gram-negative and Gram-positive bacteria.

CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an 50 of 60 nM.

Didemnin B is a depsipeptide extracted from the marine tunicate Trididemnin cyanophorum. Didemnin B can be used for the research of cancer.

Icenticaftor, also known as QBW251 is a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

A potent and specific nuclear export inhibitor that binds to and inhibits CRM1 (XPO1).

Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.

SU 16f is a potent and selective PDGFRβ inhibitor with IC50 of 10 nM, displays >14-fold, >229-fold and >10,000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively.

A toxic byproduct, iminoquinone metabolite of acetaminophen that covalently binds to the active site of MIF.

Lometrexol is a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically.

PXS-5120A is a potent, irreversible inhibitor that is >300-fold selective for LOXL2 over LOX.

TDI-11861 is second-generation soluble Adenylyl Cyclase (sAC, ADCY10) inhibitor with slow dissociation rates. TDI-11861 inhibits sAC cellular with an IC50 value of 5.5 nM.

 Episilvestrol, a derivative of silvestrol, is isolated from the fruits and twigs of Aglaia silvestris, Episilvestrol exhibited potent in vitro cytotoxic activity

BMS-986278 is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM.

A potent and selective full β3 adrenergic receptor agonist with EC50 of 1.1 nM.

IL-17 modulator 4 is a prodrug of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.

BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC50 of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC50=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.

SUN 75856, also known as N-trifluoroacetyl (TFA) protected aminolink C6 phosphoramidite for the synthesis of 5'-amino-modified oligonucleotides. TFA protection is smoothly removed during ammonia deprotection, and does not require any additional steps. If necessary, the resulting oligonucleotides can be purified by ion exchange chromatography, or gel electrophoresis. This product has no formal name at the moment.

18F-BMS-986229 is a macrocyclic PD-L1 peptide PET ligand with high radiochemical purity and high specific activity for imaging PD-L1. 18F-BMS-986229 exhibits low background signals in non-PD-L1 expressing organs and generates high signals to noise ratios within PD-L1( +) tissues (tumors and NHP spleen).

BMS-986189 is a potent macrocyclic peptide-derived PD-L1 antagonist with Kd of less than 10 pM against both human and cynomolgus monkey PD-L1.

Aceclidine is a modulator of M3 muscarinic acetylcholine receptor. Aceclidine is a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. Aceclidine has the potential for the research of disorders such as refractive errors of the eye, xerostomia, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, and esotropia (extracted from patent US20150290125A1/US20110091459A1).

Emprumapimod is a potent, orally bioavailable and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.

Isothiouronium is a functional group with the formula [RSC(NH2)2]+ (R = alkyl, aryl) and is the acid salt of isothiourea.

Sultosilic acid, piperazine salt is a lipid lowering drug. It causes significant shortening of the euglobulin lysis time and a significant diminution of platelet adhesiveness, as well as statistically significant decrease of total cholesterol, triglycerides, beta- and pre-beta-cholesterol and an increase of alpha-cholesterol.

F-14512 is a DNA topoisomerase II inhibitor potentially for the treatment of acute myeloid leukemia.

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

Novel PDZ binding kinase (PBK) inhibitor.